NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Forecast & News

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Wednesday, October, 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.47 by $0.32. The biopharmaceutical company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.24 billion. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. Alexion Pharmaceuticals's revenue was up 23.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.02 earnings per share. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals issued an update on its FY19 earnings guidance on Wednesday, October, 23rd. The company provided EPS guidance of $10.25-10.40 for the period, compared to the Thomson Reuters consensus estimate of $9.93. The company issued revenue guidance of $4.86-4.89 billion, compared to the consensus revenue estimate of $4.84 billion.

19 Wall Street analysts have issued 12 month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $125.00 to $186.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $156.89 in the next year. This suggests a possible upside of 37.8% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.

News headlines about ALXN stock have trended very positive this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Alexion Pharmaceuticals.

Alexion Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,240,000 shares, an increase of 9.1% from the October 31st total of 2,970,000 shares. Based on an average daily trading volume, of 2,250,000 shares, the short-interest ratio is currently 1.4 days. Approximately 1.5% of the company's shares are short sold. View Alexion Pharmaceuticals' Current Options Chain.

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Celgene (CELG), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), AbbVie (ABBV), Biogen (BIIB), Allergan (AGN) and UnitedHealth Group (UNH).

Alexion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.91%), Orbimed Advisors LLC (0.75%), Redmile Group LLC (0.53%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Pictet Asset Management Ltd. (0.42%) and First Trust Advisors LP (0.30%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., First Trust Advisors LP, Orbimed Advisors LLC, State Street Corp, State of Tennessee Treasury Department, State of New Jersey Common Pension Fund D, Calamos Advisors LLC and Parametric Portfolio Associates LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

ALXN stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Worldquant Millennium Advisors LLC, Man Group plc, Point72 Asset Management L.P., Krensavage Asset Management LLC, Phoenix Holdings Ltd., Squarepoint Ops LLC and Empire Life Investments Inc.. View Insider Buying and Selling for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $113.89.

Alexion Pharmaceuticals has a market capitalization of $25.20 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.60 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.View Additional Information About Alexion Pharmaceuticals.

The official website for Alexion Pharmaceuticals is http://www.alexion.com/.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]